Back to search results

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Abroad (travel likely)RecruitingPHASE1

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Boston Children's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Elizabeth DeWitt, MD) · gene.therapy@childrens.harvard.edu

  • Mayo Clinic, Rochester, Minnesota, United States

    Contact: Study coordinator (Kolawole Olarinoye) · Olarinoye.Kolawole@mayo.edu · 507-293-1564
    Contact: Principal Investigator (John Giudicessi, MD)

  • Cleveland Clinic, Cleveland, Ohio, United States

    Contact: Study coordinator (Paige Ewing) · ewingp@ccf.org · 216-445-8798
    Contact: Principal Investigator (Peter Aziz, MD)

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • St. Paul's Hospital, Vancouver, British Columbia, Canada

    Contact: Study coordinator (Brianna Davies) · brianna.davies@phc.ca · 604-682-2344
    Contact: Principal Investigator (Thomas Roston, MD)
View source on ClinicalTrials.gov(opens in a new tab)